No Association Found Between Opioid Use, Breast Cancer Recurrence
the Cancer Therapy Advisor take:
No clinical evidence was found to support a relationship between opioid prescriptions used to manage pain and risk of breast cancer recurrence, according to an article published online in the journal Cancer.
A total of 34,188 patients with incident, early stage breast cancer diagnosed between 1996 and 2008 in Denmark were identified from the Danish Breast Cancer Cooperative Group Registry. Data regarding opioid prescriptions were gathered from the Danish National Prescription Registry.
Results showed no correlation between ever-use of opioids (regardless of opioid type, strength, chronicity of use, or cumulative dose) and breast cancer recurrence (crude hazard ratio [HR], 0.98; 95% CI: 0.90, 1.1; adjusted HR, 1.0; 95% CI: 0.92, 1.1).
Furthermore, breast cancer recurrence rates were reduced among patients who used strongly (but not weakly) immunosuppressive opioids. The authors noted this could have possibly been due to channeling bias among those with a high competing risk.
The study argued the findings were important for patients with cancer given that opioids are commonly used to manage pain related to comorbid conditions.
No clinical evidence found to support a relationship between opioid prescriptions used to manage pain and risk of breast cancer recurrence.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Radical Prostatectomy Compared With Watchful Waiting in Localized Prostate Cancer
- Immunotherapy in Glioblastoma: Peaks and Pits
- Treatment Guidelines in Cancer: Assessing Industry Influence on Recommendations
- American Society of Breast Surgeons Recommends Genetic Testing for All Patients With Breast Cancer
- No Benefit Seen From HSCT in Hypodiploid B-ALL
- Patients With CP-CML Deemed Less Likely to Continue Taking Generic Imatinib
- Opinion: Understanding the FDA's Take on Cannabidiol